조찬영 (울산대학교 의과대학, 서울아산병원) | 한빛사논문 > 한빛사

한빛사논문

조회895

울산대학교 의과대학, 서울아산병원

Hepatology, First published:23 April 2020 | https://doi.org/10.1002/hep.31289 Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus‐Related Hepatocellular Carcinoma after Surgical Resection

Jonggi Choi, MD, PhD,^1* Chanyoung Jo, MD,^2* Young-Suk Lim, MD, PhD^1#

¹Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
²Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

^*J Choi and C Jo contributed equally to this work and deserve co-first authorship.
^#Corresponding author

Abstract

Studies have suggested that tenofovir disoproxil fumarate (TDF) treatment is associated with a significantly lower risk of hepatocellular carcinoma (HCC) occurrence when compared to entecavir (ETV) therapy in chronic hepatitis B patients. We aimed to compare HCC recurrence and survival of patients treated with TDF or ETV after surgical resection for hepatitis B virus (HBV)‐related HCC. This historical cohort study included 1,695 consecutive patients treated with ETV (n=813) or TDF (n=882) after curative‐intent hepatectomy for HBV‐related HCC of Barcelona Clinic Liver Cancer stage 0 or A in Korea between 2010 and 2018. HCC recurrence and overall survival of patients were compared between ETV and TDF groups by propensity score‐matched and multivariable‐adjusted Cox regression analyses from the date of hepatectomy for HCC. Mean age of the study patients was 54.8 years and 1,294 patients (76.3%) were male. During median follow‐up duration of 37.6 months with continued ETV or TDF therapy, 561 (33.1%) patients developed HCC recurrence, 144 (8.4%) died, and 22 (1.3%) received liver transplant. Compared with ETV, TDF therapy was associated with significantly higher recurrence‐free (P=0.02) and overall survival (P=0.03) rates by propensity score‐matched analysis. By multivariable‐adjusted analysis, TDF group was associated with significantly lower rates of HCC recurrence (HR, 0.82; 95% CI, 0.68‐0.98; P=0.03), and death or transplantation (HR, 0.62; 95% CI, 0.44‐0.88; P=0.01). TDF therapy was an independent protective factor for both early (<2 years; HR, 0.79; P=0.03) and late (≥2 years; HR, 0.68; P=0.03) postoperative HCC recurrence.

논문정보

형식Research article
게재일2020년 04월 (BRIC 등록일 2020-05-04)
연구진국내 연구진
분야 의약학 > 응용의학

댓글 작성 로그인

CV 열람하기

연락처 보기